Contineum Therapeutics CTNM
NASDAQ CTNM
$10.77 +0.21 (+1.99%)
At close: Nov 11, 2026 · 4:00 PM EST

Contineum Therapeutics (CTNM) Preferred Stock Liabilities (2023 - 2024)

Updated

Contineum Therapeutics (CTNM) reported Preferred Stock Liabilities of $192.62 million for Q1 2024, unchanged from the prior quarter.

Analysis

Contineum Therapeutics (CTNM) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Contineum Therapeutics 405.40 Mn -584.86 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 192.62 Mn
Dec 31, 2023 192.62 Mn
API Access

Contineum Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CTNM&period=max&api_key=YOUR_API_KEY